{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:25:06Z","timestamp":1791638706400,"version":"4.3.4"},"reference-count":158,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2967\/jnumed.121.262186","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T16:00:30Z","timestamp":1662048030000},"page":"1302-1315","source":"Crossref","is-referenced-by-count":94,"title":["Pretargeting: A Path Forward for Radioimmunotherapy"],"prefix":"10.2967","volume":"63","author":[{"given":"Sarah M.","family":"Cheal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2022090212400752000_63.9.1302.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"2022090212400752000_63.9.1302.2","first-page":"OC39","article-title":"The success and failure of radioimmunotherapy for lymphoma","volume":"47","author":"Wahl","year":"2016","journal-title":"Endocrine Abstracts."},{"key":"2022090212400752000_63.9.1302.3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ijrobp.2020.12.002","article-title":"Overcoming barriers to radiopharmaceutical therapy (RPT): an overview from the NRG-NCI working group on dosimetry of radiopharmaceutical therapy","volume":"109","author":"Divgi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2022090212400752000_63.9.1302.4","doi-asserted-by":"crossref","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"2022090212400752000_63.9.1302.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2022090212400752000_63.9.1302.6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jlcr.3622","article-title":"Aligning physics and physiology: engineering antibodies for radionuclide delivery","volume":"61","author":"Tsai","year":"2018","journal-title":"J Labelled Comp Radiopharm."},{"key":"2022090212400752000_63.9.1302.7","doi-asserted-by":"crossref","unstructured":"Parakh S Lee ST Gan HK Scott AM . Radiolabeled antibodies for cancer imaging and therapy. Cancers (Basel). 2022;14:1454.","DOI":"10.3390\/cancers14061454"},{"key":"2022090212400752000_63.9.1302.8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","article-title":"State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET","volume":"32","author":"Chomet","year":"2021","journal-title":"Bioconjug Chem."},{"key":"2022090212400752000_63.9.1302.9","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.2967\/jnumed.116.186940","article-title":"Theranostics using antibodies and antibody-related therapeutics","volume":"58(suppl 2)","author":"Moek","year":"2017","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"2022090212400752000_63.9.1302.11","first-page":"845","article-title":"The use of paired labeling in the determination of tumor-localizing antibodies","volume":"17","author":"Pressman","year":"1957","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.12","first-page":"1488","article-title":"Experimental radiation therapy of tumors with I-131-carrying antibodies to fibrin","volume":"20","author":"Bale","year":"1960","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.13","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"2022090212400752000_63.9.1302.14","first-page":"413","article-title":"Imaging and therapy of cancer with radiolabeled monoclonal antibodies","volume":"288","author":"Goldenberg","year":"1989","journal-title":"Prog Clin Biol Res."},{"key":"2022090212400752000_63.9.1302.15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/07357908409040313","article-title":"Radioimmunodetection and radioimmunotherapy","volume":"2","author":"Larson","year":"1984","journal-title":"Cancer Invest."},{"key":"2022090212400752000_63.9.1302.16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:5+<1243::AID-CNCR2820451334>3.0.CO;2-1"},{"key":"2022090212400752000_63.9.1302.17","doi-asserted-by":"publisher","DOI":"10.1038\/316265a0"},{"key":"2022090212400752000_63.9.1302.18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00006231-198608000-00002","article-title":"Monoclonal antibody hapten radiopharmaceutical delivery","volume":"7","author":"Goodwin","year":"1986","journal-title":"Nucl Med Commun."},{"key":"2022090212400752000_63.9.1302.19","first-page":"226","article-title":"Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens","volume":"29","author":"Goodwin","year":"1988","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.20","first-page":"6650","article-title":"Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma","volume":"51","author":"Stickney","year":"1991","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.21","first-page":"1294","article-title":"Investigations of avidin and biotin for imaging applications","volume":"28","author":"Hnatowich","year":"1987","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.22","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-198811000-00010"},{"key":"2022090212400752000_63.9.1302.23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.2910410727","article-title":"In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization","volume":"2","author":"Paganelli","year":"1988","journal-title":"Int J Cancer Suppl."},{"key":"2022090212400752000_63.9.1302.24","doi-asserted-by":"publisher","DOI":"10.1021\/bc015574n"},{"key":"2022090212400752000_63.9.1302.25","doi-asserted-by":"publisher","DOI":"10.1021\/bc970152s"},{"key":"2022090212400752000_63.9.1302.26","first-page":"1791","article-title":"Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication","volume":"31","author":"Kalofonos","year":"1990","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.27","first-page":"5960","article-title":"Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients","volume":"51","author":"Paganelli","year":"1991","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.28","doi-asserted-by":"crossref","unstructured":"Kraeber-Bod\u00e9r\u00e9 F Rousseau C Bodet-Milin C . A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol. 2015;6:54.","DOI":"10.3389\/fphar.2015.00054"},{"key":"2022090212400752000_63.9.1302.29","doi-asserted-by":"crossref","unstructured":"Paganelli G Chinol M Grana C .Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: Bergmann H Kroiss A Sinzinger H , eds. Radioactive Isotopes in Clinical Medicine and Research: Springer; 1997:513\u2013517.","DOI":"10.1007\/978-3-0348-7772-5_86"},{"key":"2022090212400752000_63.9.1302.30","doi-asserted-by":"crossref","unstructured":"Papi S Grana CG Bartolomei M .Pretargeted radioimmunotherapy in cancer: an overview. In: Hayat MA , ed. Methods of Cancer Diagnosis, Therapy, and Prognosis: General Overviews, Head and Neck Cancer and Thyroid Cancer. Springer; 2010:80\u201398.","DOI":"10.1007\/978-90-481-3186-0_7"},{"key":"2022090212400752000_63.9.1302.31","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050397"},{"key":"2022090212400752000_63.9.1302.32","first-page":"1813","article-title":"Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin\/biotin system","volume":"39","author":"Goodwin","year":"1998","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.33","doi-asserted-by":"publisher","DOI":"10.1021\/bc970101v"},{"key":"2022090212400752000_63.9.1302.34","doi-asserted-by":"publisher","DOI":"10.1021\/bc00019a013"},{"key":"2022090212400752000_63.9.1302.35","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2699::AID-CNCR48>3.0.CO;2-4"},{"key":"2022090212400752000_63.9.1302.36","first-page":"3479","article-title":"In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer","volume":"54","author":"Bos","year":"1994","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.37","doi-asserted-by":"crossref","unstructured":"Liu G . Use of morpholino oligomers for pretargeting. In: Moulton HM Moulton JD , eds. Morpholino Oligomers: Methods and Protocols. Springer; 2017:161\u2013179.","DOI":"10.1007\/978-1-4939-6817-6_14"},{"key":"2022090212400752000_63.9.1302.38","first-page":"156","article-title":"Preclinical optimization of pretargeted radioimmunotherapy components: high efficiency, curative 90Y delivery to mouse tumor xenografts","volume":"2","author":"Axworthy","year":"1996","journal-title":"Tumor Targeting."},{"key":"2022090212400752000_63.9.1302.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1802"},{"key":"2022090212400752000_63.9.1302.40","first-page":"438","article-title":"Phase I dose escalation trial of pretargeted radioimmunotherapy (PRIT) with 90yttrium","volume":"17","author":"Murtha","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2022090212400752000_63.9.1302.41","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2000.15.15"},{"key":"2022090212400752000_63.9.1302.42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/cbr.1999.14.381","article-title":"Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10\/streptavidin","volume":"14","author":"Breitz","year":"1999","journal-title":"Cancer Biother Radiopharm."},{"key":"2022090212400752000_63.9.1302.43","first-page":"406","article-title":"Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody\/streptavidin in patients with metastatic colon cancer","volume":"6","author":"Knox","year":"2000","journal-title":"Clin Cancer Res."},{"key":"2022090212400752000_63.9.1302.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2003.08.004"},{"key":"2022090212400752000_63.9.1302.45","first-page":"512","article-title":"Patient-specific dosimetry of indium-111-and yttrium-90-labeled monoclonal antibody CC49","volume":"38","author":"Leichner","year":"1997","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.46","first-page":"642","article-title":"Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies","volume":"46","author":"Shen","year":"2005","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.47","first-page":"140","article-title":"Pretargeted radioimmunotherapy with a single-chain antibody\/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose","volume":"47","author":"F\u00f6rster","year":"2006","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0171"},{"key":"2022090212400752000_63.9.1302.49","first-page":"5755","article-title":"Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N\u2032,N\u2032\u2032,N\u2032\u2032\u2032-tetraacetic acid (DOTA)-biotin","volume":"62","author":"Yao","year":"2002","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.50","first-page":"1201","article-title":"Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein","volume":"46","author":"Sato","year":"2005","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.51","first-page":"867","article-title":"Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2","volume":"45","author":"Cheung","year":"2004","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92225-3"},{"key":"2022090212400752000_63.9.1302.53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2022090212400752000_63.9.1302.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2535"},{"key":"2022090212400752000_63.9.1302.55","first-page":"131","article-title":"Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin","volume":"41","author":"Breitz","year":"2000","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.56","first-page":"6663","article-title":"A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy","volume":"60","author":"Schultz","year":"2000","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3284"},{"key":"2022090212400752000_63.9.1302.58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437788100"},{"key":"2022090212400752000_63.9.1302.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0874"},{"key":"2022090212400752000_63.9.1302.60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056895"},{"key":"2022090212400752000_63.9.1302.61","first-page":"1358","article-title":"In vitro and in\u00a0vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate","volume":"30","author":"Le Doussal","year":"1989","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.62","first-page":"5937","article-title":"Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB\/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy","volume":"54","author":"Goodwin","year":"1994","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.63","first-page":"1662","article-title":"Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response","volume":"34","author":"Le Doussal","year":"1993","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.64","first-page":"1267","article-title":"Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA\/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer","volume":"34","author":"Peltier","year":"1993","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.65","first-page":"1172","article-title":"Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA \u00d7 anti-DTPA-indium bispecific antibody","volume":"39","author":"Barbet","year":"1998","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.66","first-page":"507","article-title":"Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA\/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer","volume":"38","author":"Vuillez","year":"1997","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.67","first-page":"1853","article-title":"Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer","volume":"37","author":"Bardi\u00e8s","year":"1996","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.68","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1999.14.153"},{"key":"2022090212400752000_63.9.1302.69","doi-asserted-by":"publisher","DOI":"10.1021\/bc0000379"},{"key":"2022090212400752000_63.9.1302.70","first-page":"198","article-title":"Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft","volume":"40","author":"Kraeber-Bod\u00e9r\u00e9","year":"1999","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.71","first-page":"3190s","article-title":"Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I\/II clinical trial","volume":"5(suppl)","author":"Kraeber-Bod\u00e9r\u00e9","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2022090212400752000_63.9.1302.72","first-page":"3259s","article-title":"Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen\/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I\/II trial","volume":"5(suppl)","author":"Vuillez","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2022090212400752000_63.9.1302.73","first-page":"3973S","article-title":"Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen \u00d7 anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial","volume":"9","author":"Kraeber-Bod\u00e9r\u00e9","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2022090212400752000_63.9.1302.74","first-page":"247","article-title":"Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial","volume":"47","author":"Kraeber-Bod\u00e9r\u00e9","year":"2006","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4917"},{"key":"2022090212400752000_63.9.1302.76","first-page":"4400","article-title":"Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate","volume":"59","author":"Boerman","year":"1999","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.77","first-page":"495","article-title":"Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models","volume":"46","author":"van Schaijk","year":"2005","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.78","first-page":"1016","article-title":"Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting","volume":"46","author":"van Schaijk","year":"2005","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1004-0006"},{"key":"2022090212400752000_63.9.1302.80","doi-asserted-by":"publisher","DOI":"10.1080\/07357900500449553"},{"key":"2022090212400752000_63.9.1302.81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.1998.17.125","article-title":"New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor","volume":"17","author":"Feng","year":"1998","journal-title":"Hybridoma."},{"key":"2022090212400752000_63.9.1302.82","doi-asserted-by":"publisher","DOI":"10.1021\/bc970083h"},{"key":"2022090212400752000_63.9.1302.83","doi-asserted-by":"publisher","DOI":"10.1021\/bc0200172"},{"key":"2022090212400752000_63.9.1302.84","first-page":"354","article-title":"A universal pretargeting system for cancer detection and therapy using bispecific antibody","volume":"63","author":"Sharkey","year":"2003","journal-title":"Cancer Res."},{"key":"2022090212400752000_63.9.1302.85","doi-asserted-by":"publisher","DOI":"10.1038\/nm1322"},{"key":"2022090212400752000_63.9.1302.86","first-page":"1678","article-title":"Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide","volume":"47","author":"McBride","year":"2006","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.87","first-page":"3886S","article-title":"Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy","volume":"9","author":"Rossi","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2022090212400752000_63.9.1302.88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1217"},{"key":"2022090212400752000_63.9.1302.89","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046185"},{"key":"2022090212400752000_63.9.1302.90","doi-asserted-by":"publisher","DOI":"10.7150\/thno.3582"},{"key":"2022090212400752000_63.9.1302.91","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1903-0"},{"key":"2022090212400752000_63.9.1302.92","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.067686"},{"key":"2022090212400752000_63.9.1302.93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1246"},{"key":"2022090212400752000_63.9.1302.94","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.12.002"},{"key":"2022090212400752000_63.9.1302.95","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bbmt.2012.11.054","article-title":"Pretargeted radioimmunotherapy using an anti-CD45 antibody-streptavidin conjugate and radiolabeled DOTA-biotin in patients with high-risk acute leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation","volume":"19(suppl)","author":"Mawad","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022090212400752000_63.9.1302.96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1058"},{"key":"2022090212400752000_63.9.1302.97","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2010.0797"},{"key":"2022090212400752000_63.9.1302.98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/cbr.2009.0738","article-title":"AvidinOX for highly efficient tissue-pretargeted radionuclide therapy","volume":"25","author":"De Santis","year":"2010","journal-title":"Cancer Biother Radiopharm."},{"key":"2022090212400752000_63.9.1302.99","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/cbr.2015.1837","article-title":"Radionuclide therapy of unresectable tumors with AvidinOX and 90Y-biotinDOTA: tongue cancer paradigm","volume":"30","author":"Albertoni","year":"2015","journal-title":"Cancer Biother Radiopharm."},{"key":"2022090212400752000_63.9.1302.100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/cbr.2009.0738","article-title":"AvidinOX for highly efficient tissue-pretargeted radionuclide therapy","volume":"25","author":"De Santis","year":"2010","journal-title":"Cancer Biother Radiopharm."},{"key":"2022090212400752000_63.9.1302.101","first-page":"3529","article-title":"Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer","volume":"17","author":"Vesci","year":"2019","journal-title":"Oncol Lett."},{"key":"2022090212400752000_63.9.1302.102","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1281"},{"key":"2022090212400752000_63.9.1302.103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120561"},{"key":"2022090212400752000_63.9.1302.104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0571"},{"key":"2022090212400752000_63.9.1302.105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2523"},{"key":"2022090212400752000_63.9.1302.106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0594"},{"key":"2022090212400752000_63.9.1302.107","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.187021"},{"key":"2022090212400752000_63.9.1302.108","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.376"},{"key":"2022090212400752000_63.9.1302.109","first-page":"1593","article-title":"Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer","volume":"41","author":"Schoffelen","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212400752000_63.9.1302.110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40658-014-0104-x","article-title":"Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy","volume":"2","author":"Woliner-van der Weg","year":"2015","journal-title":"EJNMMI Phys."},{"key":"2022090212400752000_63.9.1302.111","first-page":"84","article-title":"Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients","volume":"2","author":"Bodet-Milin","year":"2015","journal-title":"Front Med (Lausanne)."},{"key":"2022090212400752000_63.9.1302.112","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.172221"},{"key":"2022090212400752000_63.9.1302.113","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-020-04989-3","article-title":"Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study","volume":"48","author":"Touchefeu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212400752000_63.9.1302.114","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236000"},{"key":"2022090212400752000_63.9.1302.115","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.252791"},{"key":"2022090212400752000_63.9.1302.116","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.08.013"},{"key":"2022090212400752000_63.9.1302.117","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzp077"},{"key":"2022090212400752000_63.9.1302.118","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-010-0353-6"},{"key":"2022090212400752000_63.9.1302.119","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0764"},{"key":"2022090212400752000_63.9.1302.120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0933"},{"key":"2022090212400752000_63.9.1302.121","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-015-3254-8","article-title":"Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825\/GPA33 IgG bispecific immunoconjugates","volume":"43","author":"Cheal","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212400752000_63.9.1302.122","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics."},{"key":"2022090212400752000_63.9.1302.123","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.7150\/thno.48810","article-title":"Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors: safety at curative doses","volume":"10","author":"Cheal","year":"2020","journal-title":"Theranostics."},{"key":"2022090212400752000_63.9.1302.124","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/acs.bioconjchem.9b00736","article-title":"An N-acetylgalactosamino dendron-clearing agent for high-therapeutic-index DOTA-hapten pretargeted radioimmunotherapy","volume":"31","author":"Cheal","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2022090212400752000_63.9.1302.125","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0306"},{"key":"2022090212400752000_63.9.1302.126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807610"},{"key":"2022090212400752000_63.9.1302.127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2150"},{"key":"2022090212400752000_63.9.1302.128","unstructured":"Torgue J Jurek P Rojas-Quijano F ., inventors; Hoffmann-La Roche Inc., Orano Med SAS, assignees. Antibodies for chelated radionuclides and clearing agents. World Intellectual Property Organization patent WO2019202399A8. December 12, 2019."},{"key":"2022090212400752000_63.9.1302.129","first-page":"S56","article-title":"Preclinical evaluation of CEA-PRIT, a novel pretargeted alpha therapy regimen for treatment of CEA-positive tumours with Pb-212","volume":"46","author":"Frost","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212400752000_63.9.1302.130","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131243"},{"key":"2022090212400752000_63.9.1302.131","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1630"},{"key":"2022090212400752000_63.9.1302.132","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.208348"},{"key":"2022090212400752000_63.9.1302.133","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.162248"},{"key":"2022090212400752000_63.9.1302.134","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.208041"},{"key":"2022090212400752000_63.9.1302.135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cbpa.2010.09.015","article-title":"Chemically modified antibodies as diagnostic imaging agents","volume":"14","author":"Day","year":"2010","journal-title":"Curr Opin Chem Biol."},{"key":"2022090212400752000_63.9.1302.136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s43586-021-00028-z","article-title":"Bioorthogonal chemistry","volume":"1","author":"Scinto","year":"2021","journal-title":"Nat Rev Methods Primers."},{"key":"2022090212400752000_63.9.1302.137","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200906294"},{"key":"2022090212400752000_63.9.1302.138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.bioconjchem.9b00761","article-title":"Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy","volume":"31","author":"Rondon","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2022090212400752000_63.9.1302.139","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/acs.bioconjchem.7b00612","article-title":"Metal-free cycloaddition chemistry driven pretargeted radioimmunotherapy using alpha-particle radiation","volume":"28","author":"Shah","year":"2017","journal-title":"Bioconjug Chem."},{"key":"2022090212400752000_63.9.1302.140","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0503"},{"key":"2022090212400752000_63.9.1302.141","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/acs.molpharmaceut.8b00093","article-title":"Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma","volume":"15","author":"Membreno","year":"2018","journal-title":"Mol Pharm."},{"key":"2022090212400752000_63.9.1302.142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1650"},{"key":"2022090212400752000_63.9.1302.143","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/acs.molpharmaceut.9b00062","article-title":"Toward the optimization of click-mediated pretargeted radioimmunotherapy","volume":"16","author":"Membreno","year":"2019","journal-title":"Mol Pharm."},{"key":"2022090212400752000_63.9.1302.144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009960117"},{"key":"2022090212400752000_63.9.1302.145","doi-asserted-by":"crossref","first-page":"1536012118799838","DOI":"10.1177\/1536012118799838","article-title":"Adamantane\/cucurbituril: a potential pretargeted imaging strategy in immuno-PET","volume":"17","author":"Strebl","year":"2018","journal-title":"Mol Imaging."},{"key":"2022090212400752000_63.9.1302.146","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acsnano.7b08122","article-title":"Bespoke pretargeted nanoradioimmunotherapy for the treatment of non-Hodgkin lymphoma","volume":"12","author":"Au","year":"2018","journal-title":"ACS Nano."},{"key":"2022090212400752000_63.9.1302.147","doi-asserted-by":"crossref","unstructured":"Huang Z Hu Y Yang Y Huang W Wang Y Ye D . Recent advances in pretargeted imaging of tumors in\u00a0vivo. Analysis Sensing. April 21, 2022 [Epub ahead of print].","DOI":"10.1002\/anse.202200013"},{"key":"2022090212400752000_63.9.1302.148","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acsptsci.1c00007","article-title":"Lipophilicity and click reactivity determine the performance of bioorthogonal tetrazine tools in pretargeted in\u00a0vivo chemistry","volume":"4","author":"St\u00e9en","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2022090212400752000_63.9.1302.149","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current landscape in clinical pretargeted radioimmunoimaging and therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.150","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.183"},{"key":"2022090212400752000_63.9.1302.151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"225Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med."},{"key":"2022090212400752000_63.9.1302.152","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.7150\/thno.44772","article-title":"89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following \u03b1- and \u03b2-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma","volume":"10","author":"Poty","year":"2020","journal-title":"Theranostics."},{"key":"2022090212400752000_63.9.1302.153","first-page":"55","article-title":"In-vivo chemistry for pretargeted tumor imaging and therapy in mice","volume":"54","author":"Robillard","year":"2010","journal-title":"Medicamundi."},{"key":"2022090212400752000_63.9.1302.154","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0037"},{"key":"2022090212400752000_63.9.1302.155","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/cancers13030500","article-title":"Comparative evaluation of novel 177Lu-labeled PNA probes for affibody-mediated PNA-based pretargeting","volume":"13","author":"Tano","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2022090212400752000_63.9.1302.156","doi-asserted-by":"publisher","DOI":"10.1021\/bc300678y"},{"key":"2022090212400752000_63.9.1302.157","first-page":"1608","article-title":"Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten","volume":"39","author":"Hosono","year":"1998","journal-title":"J Nucl Med."},{"key":"2022090212400752000_63.9.1302.158","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7150\/thno.51215","article-title":"Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response","volume":"11","author":"Feijtel","year":"2021","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T19:41:45Z","timestamp":1662147705000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":158,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2967\/jnumed.121.262186"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262186","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}